Characterizing the Pancreatic Cancer Proteome From Pancreatic Juice
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02277834|
Recruitment Status : Completed
First Posted : October 29, 2014
Last Update Posted : May 13, 2016
|Condition or disease|
Pancreatic cancer is very difficult to detect and treat, and patients with this cancer generally live fewer years than patients with other types of cancer. Part of the reason why pancreatic cancer is so hard to treat is because it is usually discovered when it is too advanced to be able to treat. The goal of this protocol is to find a way to detect pancreatic cancer earlier, when it is still treatable in order to improve the survival of patients.
The pancreas is a gland which produces digestive juices that mix with food in the intestines. Normal patients as well as patients with pancreatic cancer produce these juices. Other researchers have collected this fluid from very small numbers of patients and their results suggest that pancreatic fluid can be used to detect pancreatic cancer. One of the major issues with these results is that pancreatic fluid from only a very few number of patients has been collected and analyzed. In order to find out whether the pancreatic fluid can be used as a standard test for pancreatic cancer, the fluid from a greater number of patients needs to be analyzed. Also, of all the different chemicals in the pancreatic fluid, in this study we will try to figure out what the most important chemicals are in diagnosing pancreatic cancer.
|Study Type :||Observational|
|Actual Enrollment :||9 participants|
|Official Title:||Characterizing the Pancreatic Adenocarcinoma Proteome From Pancreatic Juice|
|Study Start Date :||August 2014|
|Actual Primary Completion Date :||April 2016|
|Actual Study Completion Date :||April 2016|
15 patients receiving Endoscopic Retrograde Cholangiopancreatography with suspected pancreatic adenocarcinoma (localized or metastatic).
15 patients with a history of chronic pancreatitis that are having Endoscopic Retrograde Cholangiopancreatography .
non-pancreatic, non-neoplastic disorders
15 patients undergoing an Endoscopic Retrograde Cholangiopancreatography for non-pancreatic, non-neoplastic indications.
- Compare the proteomic signature of pancreatic adenocarcinoma , pancreatic cancer and control participants to the disease process [ Time Frame: 120 months from First subject enrolled ]Characterization of the proteomic signature of patients with pancreatic adenocarcinoma, pancreatic cancer, and control participants. This will be accomplished by classifying a group or set of similar proteomic profiles(once we(once we have developed from the samples obtained a list of known proteomic profiles taht are found in all pancreatic adenocarcinoma subjects) that are specific to the disease process,of pancreatic adenocarcinoma.
- Compare the proteomic profile between pancreatic cancer and pancreatitis [ Time Frame: 120 months from First subject enrolled ]Using the discovered pancreatic adenocarcinoma proteomic profile we will differentiate a documentable difference from pancreatic cancer and pancreatitis
Biospecimen Retention: Samples Without DNA
samples will be in 3 differant cohorts;
- Subject with biopsy-proven Pancreatic Adenocarcinoma of the pancreas
- Subjects witha diagnosis of Pancreatitis
- Subject with NO pancreatic abnormality
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02277834
|United States, Alabama|
|University of Alabama at Birmingham|
|Birmingham, Alabama, United States, 35294|
|Principal Investigator:||Carlo M Contreras, MD||University of Alabama at Birmingham|